Business Context and Reporting Period
Belite Bio, Inc., a foreign private issuer filing on Form 20-F, furnished this Form 6-K for May 2023. The filing reports the pricing of an underwritten public offering announced on May 30, 2023.
Offering and Key Financial Terms
| Item | Terms |
|---|---|
| ADSs offered | 2,000,000 ADSs, each representing one ordinary share |
| Warrants offered | Warrants to purchase 2,000,000 ordinary shares represented by ADSs |
| Public offering price | $15.00 per ADS and accompanying warrant |
| Warrant exercise price | $18.00 per ADS |
| Warrant term | Immediately exercisable; expires five years after issuance |
| Expected gross proceeds | Approximately $30 million, before underwriting discounts, commissions, and estimated offering expenses |
| Expected closing | On or about June 2, 2023, subject to customary closing conditions |
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity balances, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
The filing text does not provide comparative operating or financial results. The principal disclosed change is the planned capital raise through the sale of ADSs and accompanying warrants, which would increase cash resources and share-related dilution upon closing and potentially upon warrant exercise.
Guidance, Outlook, Risks, and Unusual Items
- The offering remained subject to customary closing conditions as of the filing date; the filing does not confirm the actual closing or net proceeds received.
- Gross proceeds will be reduced by underwriting discounts, commissions, and offering expenses; the filing does not state the expected net proceeds.
- The warrants have an exercise price above the offering price and may result in additional ordinary shares or ADSs being issued if exercised, causing dilution to existing shareholders.
- No management guidance, use-of-proceeds detail, operating outlook, contingencies, or new business risks are provided in the filing text.
- The offering was conducted under the company’s effective Form F-3 shelf registration statement, declared effective May 30, 2023.
Investor Verification Items
- Verify whether the offering closed as expected and determine the actual net proceeds received.
- Review the underwriting agreement and warrant form for final terms, adjustment provisions, registration rights, and other investor protections.
- Assess the potential dilution from the 2,000,000 warrants and any subsequent warrant exercises.
- Review subsequent filings for the company’s use of proceeds, cash runway, liquidity, and operating results.
- Confirm the offering price, warrant exercise price, five-year expiration, and customary closing conditions.